Feasibility and Clinical Value of CT Guided 125 IBrachytherapy for Metastatic Soft Tissue Sarcoma after First-Line Chemotherapy Failure

Brachytherapy ◽

10.1016/j.brachy.2018.04.167 ◽

2018 ◽

Vol 17 (4) ◽

pp. S94

Author(s):

Zhiqiang Mo

Keyword(s):

Soft Tissue ◽

Soft Tissue Sarcoma ◽

Clinical Value ◽

Ct Guided ◽

Metastatic Soft Tissue Sarcoma ◽

Line Chemotherapy

Download Full-text

Feasibility and clinical value of CT-guided 125I brachytherapy for metastatic soft tissue sarcoma after first-line chemotherapy failure

European Radiology ◽

10.1007/s00330-017-5036-0 ◽

2017 ◽

Vol 28 (3) ◽

pp. 1194-1203 ◽

Author(s):

Zhiqiang Mo ◽

Tao Zhang ◽

Yanling Zhang ◽

Zhanwang Xiang ◽

Huzhen Yan ◽

...

Keyword(s):

Soft Tissue ◽

Soft Tissue Sarcoma ◽

Clinical Value ◽

Ct Guided ◽

125I Brachytherapy ◽

Metastatic Soft Tissue Sarcoma ◽

Line Chemotherapy

Download Full-text

Feasibility and Clinical Value of CT-Guided 125I Brachytherapy for Metastatic Soft Tissue Sarcoma after First-Line Chemotherapy Failure

Brachytherapy ◽

10.1016/j.brachy.2019.04.179 ◽

2019 ◽

Vol 18 (3) ◽

pp. S85

Author(s):

Zhiqiang Mo ◽

Jian He ◽

Xiaoming Chen

Keyword(s):

Soft Tissue ◽

Soft Tissue Sarcoma ◽

Clinical Value ◽

Ct Guided ◽

125I Brachytherapy ◽

Metastatic Soft Tissue Sarcoma ◽

Line Chemotherapy

Download Full-text

Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: An European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group randomised phase II and pharmacogenetic study

European Journal of Cancer ◽

10.1016/j.ejca.2013.10.002 ◽

2014 ◽

Vol 50 (2) ◽

pp. 388-396 ◽

Author(s):

H. Gelderblom ◽

J.Y. Blay ◽

B.M. Seddon ◽

M. Leahy ◽

I. Ray-Coquard ◽

...

Keyword(s):

Soft Tissue ◽

Soft Tissue Sarcoma ◽

Phase Ii ◽

Bone Sarcoma ◽

Pharmacogenetic Study ◽

European Organisation ◽

Metastatic Soft Tissue Sarcoma ◽

Line Chemotherapy

Download Full-text

Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: An EORTC Soft Tissue and Bone Sarcoma Group randomized phase II study.

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.10037 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 10037-10037 ◽

Author(s):

H. Gelderblom ◽

J. Blay ◽

B. M. Seddon ◽

M. Leahy ◽

I. L. Ray-Coquard ◽

...

Keyword(s):

Soft Tissue ◽

Soft Tissue Sarcoma ◽

Phase Ii ◽

Phase Ii Study ◽

Bone Sarcoma ◽

Randomized Phase Ii ◽

Metastatic Soft Tissue Sarcoma ◽

Line Chemotherapy

Download Full-text

Randomised phase 2 study comparing the efficacy and safety of the oral tyrosine kinase inhibitor nintedanib with single agent ifosfamide in patients with advanced, inoperable, metastatic soft tissue sarcoma after failure of first-line chemotherapy: EORTC-1506-STBSG “ANITA”

European Journal of Cancer ◽

10.1016/j.ejca.2021.04.015 ◽

2021 ◽

Vol 152 ◽

pp. 26-40

Author(s):

Patrick Schöffski ◽

Maud Toulmonde ◽

Anna Estival ◽

Gloria Marquina ◽

Monika Dudzisz-Śledź ◽

...

Keyword(s):

Soft Tissue ◽

Soft Tissue Sarcoma ◽

Kinase Inhibitor ◽

Single Agent ◽

Phase 2 ◽

Efficacy And Safety ◽

Phase 2 Study ◽

Metastatic Soft Tissue Sarcoma ◽

Line Chemotherapy

Download Full-text

Results of a Randomised Phase III Trial (EORTC 62012) of Single Agent Doxorubicin Versus Doxorubicin Plus Ifosfamide as First Line Chemotherapy for Patients with Advanced or Metastatic Soft Tissue Sarcoma: A Survival Study by the Eortc Soft Tissue and Bone Sarcoma Group

Annals of Oncology ◽

10.1016/s0923-7534(20)34351-9 ◽

2012 ◽

Vol 23 ◽

pp. ixe28 ◽

Author(s):

I. Judson ◽

J. Verweij ◽

H. Gelderblom ◽

J.T. Hartmann ◽

P. Schöffski ◽

...

Keyword(s):

Soft Tissue ◽

Soft Tissue Sarcoma ◽

Single Agent ◽

Bone Sarcoma ◽

Phase Iii ◽

Phase Iii Trial ◽

Survival Study ◽

Metastatic Soft Tissue Sarcoma ◽

Line Chemotherapy

Download Full-text

Study on the Treatment of Soft Tissue Sarcoma With First-line Chemotherapy Failure by Anrotenil Hydrochloride Capsule

Case Medical Research ◽

10.31525/ct1-nct04223583 ◽

2020 ◽

Author(s):

Keyword(s):

Soft Tissue ◽

Soft Tissue Sarcoma ◽

Line Chemotherapy

Download Full-text

1652P A prospective, single-arm phase II study of pegylated-liposome doxorubincin combined with ifosfamide as first-line treatment for patients with advanced or metastatic soft tissue sarcoma

Annals of Oncology ◽

10.1016/j.annonc.2020.08.1878 ◽

2020 ◽

Vol 31 ◽

pp. S986

Author(s):

X. Liu ◽

X. Zhang ◽

J. Cao ◽

H. Wang ◽

X. Wu ◽

...

Keyword(s):

Soft Tissue ◽

Soft Tissue Sarcoma ◽

Phase Ii ◽

Phase Ii Study ◽

Line Treatment ◽

Pegylated Liposome ◽

Metastatic Soft Tissue Sarcoma ◽

First Line Treatment

Download Full-text

Phase II study of liposomal daunorubicin and ifosfamide (IDx) as first line chemotherapy in soft tissue sarcoma

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.14_suppl.9011 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 9011-9011

Author(s):

P. M. Deckert ◽

J. M. Siehl ◽

E. Thiel ◽

A. Schmittel ◽

G. Hütter ◽

...

Keyword(s):

Soft Tissue ◽

Soft Tissue Sarcoma ◽

Phase Ii ◽

Phase Ii Study ◽

Liposomal Daunorubicin ◽

Line Chemotherapy

Download Full-text

3439 Prognostic factors in soft tissue sarcoma patients with lung metastases only receiving first-line chemotherapy. An exploratory, retrospective analysis on fifteen trials of the European Organization for Research and Treatment of Cancer - Soft Tissue and Bone Sarcoma Group (EORTC-STBSG)

European Journal of Cancer ◽

10.1016/s0959-8049(16)31912-8 ◽

2015 ◽

Vol 51 ◽

pp. S701

Author(s):

L. Lindner ◽

S. Litiere ◽

S. Sleijfer ◽

I. Judson ◽

A. Italiano ◽

...

Keyword(s):

Prognostic Factors ◽

Soft Tissue ◽

Soft Tissue Sarcoma ◽

Retrospective Analysis ◽

Lung Metastases ◽

Bone Sarcoma ◽

European Organization ◽

Line Chemotherapy

Download Full-text